Effects of Pancreatic Enzyme Replacement Therapy on Body Weight and Nutritional Assessments After Pancreatoduodenectomy in a Randomized Trial.
We studied the effects of pancreatic enzyme replacement therapy (PERT) on body weight, nutritional status, and quality of life (QoL) in patients with pancreatic exocrine insufficiency after pancreatoduodenectomy. We performed a randomized, double-blind trial of 304 patients who underwent pancreatoduodenectomy at 7 tertiary referral hospitals in South Korea. Patients with fecal levels of elastase of 200 μg/g at or less, before and after surgery, were randomly assigned to groups that received PERT (a single capsule of 40,000 IU pancreatin, Norzyme, 3 times each day during meals for 3 months; n=151) or placebo (n=153). Protocol completion was defined as taking more than two thirds of the total dose without taking other digestive enzymes; the protocol was completed by 71 patients in the PERT group and 93 patients in the placebo group. Patients received physical examination, oral glucose tolerance tests, and blood tests at baseline and at month 3 of the study period. The primary endpoint was change in body weight. Secondary endpoints were changes in bowel habits, nutritional parameters, and QoL. In the per-protocol analysis, 3 months after the study began, patients in the PERT group gained a mean 1.09 kg in weight and patients in the placebo lost a mean 2.28 kg (difference between groups, 3.37 kg; P<.001). However, no difference in body weight was observed between groups in the intent to treat analysis. Three months after the study began, mean serum levels of prealbumin increased by 10.9 mg/dL in the PERT group and increased by 7.8 mg/dL prealbumin in the placebo group (P=.002). Poor compliance to PERT was a significant risk factor for weight loss (P<.001). There was no significant difference in QoL scores between groups. In the intent to treat analysis of data from a randomized trial, we found no significant effect of PERT on mean body weights of patients with pancreatic exocrine insufficiency after pancreatoduodenectomy. However, with active education and monitoring, PERT could increase body weight and nutritional parameters. ClinicalTrials.gov no: NCT02127021.